{'fraction_non_alphanumeric': 0.02695956065901148, 'fraction_numerical': 0.008487269096355467, 'mean_word_length': 6.34065934065934, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Advances in our understanding of the molecular basis of disorders of platelet function

Summary.  Genetic defects of platelet function give rise to mucocutaneous bleeding of varying severity because platelets fail to fulfil their haemostatic role after vessel injury. Abnormalities of pathways involving glycoprotein (GP) mediators of adhesion (Bernard–Soulier syndrome, platelet‐type von Willebrand disease) and aggregation (Glanzmann thrombasthenia) are the most studied and affect the GPIb‐IX‐V complex and integrin αIIbβ3, respectively. Leukocyte adhesion deficiency‐III combines Glanzmann thrombasthenia with infections and defects of kindlin‐3, a mediator of integrin activation. Agonist‐specific deficiencies in platelet aggregation relate to mutations of primary receptors for ADP (P2Y12), thromboxane A2 (TXA2R) and collagen (GPVI); however, selective abnormalities of intracellular signalling pathways remain better understood in mouse models. Defects of secretion from δ‐granules are accompanied by pigment defects in the Hermansky–Pudlak and Chediak–Higashi syndromes; they concern multiple genes and protein complexes involved in secretory organelle biogenesis and function. Quebec syndrome is linked to a tandem duplication of the urokinase plasminogen activator (PLAU) gene while locus assignment to chromosome 3p has advanced the search for the gene(s) responsible for α‐granule deficiency in the gray platelet syndrome. Defects of α‐granule biosynthesis also involve germline VPS33B mutations in the ARC (arthrogryposis, renal dysfunction and cholestasis) syndrome. A mutation in transmembrane protein 16F (TMEM16F) has been linked to a defective procoagulant activity and phosphatidylserine expression in the Scott syndrome. Cytoskeletal dysfunction (with platelet anisotrophy) occurs not only in the Wiskott‐Aldrich syndrome but also in filamin A deficiency or MYH9‐related disease while GATA1 mutations or RUNX1 haploinsufficiency can affect expression of multiple platelet proteins.